FDA Agrees With AtheroNova’s Clinical Development Plan as Proposed

AtheroNova has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the FDA for its AHRO-001, a compound for the treatment of atherosclerosis.
Yahoo! Finance